Omnicell Stock Today
| OMCL Stock | USD 33.00 0.72 2.23% |
PerformanceVery Weak
| Odds Of DistressVery Low
|
Omnicell is selling for 33.00 as of the 16th of March 2025. This is a 2.23 percent increase since the beginning of the trading day. The stock's lowest day price was 32.4. Omnicell has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 7th of August 2001 | Category Healthcare | Classification Health Care |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California. The company has 46.76 M outstanding shares of which 1.83 M shares are now shorted by private and institutional investors with about 3.88 trading days to cover. More on Omnicell
Moving against Omnicell Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Omnicell Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Randall Lipps | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Computers (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Technology, Health Care Equipment & Services, Health Care, Nasdaq CTA Artificial, SP Small-Cap 600, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Computers, Health Care, Health Care Technology, Health Information Services, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOmnicell can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Omnicell's financial leverage. It provides some insight into what part of Omnicell's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Omnicell (OMCL) is traded on NASDAQ Exchange in USA. It is located in 4220 North Freeway, Fort Worth, TX, United States, 76137 and employs 3,670 people. Omnicell is listed under Health Care Technology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.54 B. Omnicell conducts business under Health Care Technology sector and is part of Health Care industry. The entity has 46.76 M outstanding shares of which 1.83 M shares are now shorted by private and institutional investors with about 3.88 trading days to cover.
Omnicell currently holds about 244.95 M in cash with 187.72 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.53.
Check Omnicell Probability Of Bankruptcy
Ownership AllocationThe majority of Omnicell outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Omnicell to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Omnicell. Please pay attention to any change in the institutional holdings of Omnicell as this could imply that something significant has changed or is about to change at the company.
Check Omnicell Ownership Details
Omnicell Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-12-31 | 940.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 873.5 K | |
| Federated Hermes Inc | 2024-12-31 | 787.7 K | |
| Royal Bank Of Canada | 2024-12-31 | 712.2 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 639.8 K | |
| Mirae Asset Global Etfs Holdings Ltd. | 2024-12-31 | 639.5 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 616.2 K | |
| Northern Trust Corp | 2024-12-31 | 565 K | |
| Millennium Management Llc | 2024-12-31 | 499.8 K | |
| Blackrock Inc | 2024-12-31 | 8.2 M | |
| Vanguard Group Inc | 2024-12-31 | 5.6 M |
Omnicell Historical Income Statement
Omnicell Stock Against Markets
Omnicell Corporate Management
| Joseph Spears | Principal Chief Accounting Officer | Profile | |
| Kathleen Nemeth | Senior Relations | Profile | |
| Vicki MacDevitt | Chief Staff | Profile | |
| Sara Dalmasso | Senior International | Profile | |
| Minoo Mortazavi | Senior Operations | Profile | |
| Corey Manley | Executive Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.558 | Earnings Share 0.27 | Revenue Per Share | Quarterly Revenue Growth 0.186 | Return On Assets |
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.